Ocular Therapeutix Incorporated (NASDAQ:OCUL) had an increase of 5.77% in short interest. OCUL’s SI was 6.28M shares in April as released by FINRA. Its up 5.77% from 5.94M shares previously. With 880,500 avg volume, 7 days are for Ocular Therapeutix Incorporated (NASDAQ:OCUL)’s short sellers to cover OCUL’s short positions. The SI to Ocular Therapeutix Incorporated’s float is 31.93%. About 189,673 shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has risen 26.13% since September 13, 2016 and is uptrending. It has outperformed by 16.20% the S&P500.
Awm Investment Company Inc increased Neophotonics Corporation (NPTN) stake by 4.56% reported in 2016Q4 SEC filing. Awm Investment Company Inc acquired 80,000 shares as Neophotonics Corporation (NPTN)’s stock declined 32.94%. The Awm Investment Company Inc holds 1.83M shares with $19.82M value, up from 1.75 million last quarter. Neophotonics Corporation now has $319.96M valuation. The stock rose 0.78% or $0.06 reaching $7.78 per share. About 383,159 shares traded. NeoPhotonics Corp (NYSE:NPTN) has declined 55.76% since September 13, 2016 and is downtrending. It has underperformed by 65.69% the S&P500.
Among 5 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ocular Therapeutix had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Buy” rating given on Wednesday, August 5 by Nomura. Morgan Stanley maintained the shares of OCUL in report on Tuesday, June 7 with “Overweight” rating. The firm has “Overweight” rating by Morgan Stanley given on Thursday, April 28. The firm has “Equal Weight” rating given on Thursday, August 13 by Morgan Stanley. JMP Securities initiated the stock with “Outperform” rating in Thursday, August 11 report. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) earned “Overweight” rating by Cantor Fitzgerald on Friday, February 10. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, November 15. Morgan Stanley upgraded the stock to “Overweight” rating in Thursday, February 18 report. On Friday, October 23 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”.
Ocular Therapeutix, Inc. is a biopharmaceutical company. The company has market cap of $254.78 million. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. It currently has negative earnings. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Among 7 analysts covering NeoPhotonics (NYSE:NPTN), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. NeoPhotonics had 13 analyst reports since August 7, 2015 according to SRatingsIntel. Needham maintained NeoPhotonics Corp (NYSE:NPTN) rating on Monday, October 31. Needham has “Strong Buy” rating and $24 target. Needham maintained the shares of NPTN in report on Wednesday, March 15 with “Strong Buy” rating. The rating was maintained by Needham with “Strong Buy” on Tuesday, December 20. The rating was maintained by Needham with “Strong Buy” on Monday, September 12. The stock of NeoPhotonics Corp (NYSE:NPTN) has “Outperform” rating given on Monday, August 10 by Raymond James. The stock has “Outperform” rating by Raymond James on Friday, November 6. The rating was downgraded by B. Riley & Co on Friday, August 7 to “Neutral”. Piper Jaffray initiated the shares of NPTN in report on Tuesday, February 23 with “Overweight” rating. Raymond James upgraded the shares of NPTN in report on Wednesday, February 3 to “Strong Buy” rating. Northland Capital maintained NeoPhotonics Corp (NYSE:NPTN) rating on Monday, December 7. Northland Capital has “Outperform” rating and $13 target.
